SHERMAN MATTHEW L (EVP & Chief Medical Officer) sold 2.3% of their position (2.62K shares) of DECIPHERA PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $40.8K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/20/2024ACC: 0000950170-24-017085
Officer· EVP & Chief Medical Officer
Since Oct 2019
+83.76K
Net shares
Net buyer
$40.8K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
86.38K acquired · 2.62K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+17.27K
Price / share
—
Trade value
—
% of position
18.4%
2/15/2024
94.08K→111.35K
Common Stock
Direct
Shares
−2.62K
Price / share
$15.62
Trade value
$40.84K
% of position
2.3%
2/16/2024
111.35K→108.74K
Total
Net shares
+14.66K
Net value
-$40.84K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/15/2024 | A · Award | +17.27K | — | — | 18.4% | 94.08K | 111.35K |
| Common Stock Direct | 2/16/2024 | S · Sale | −2.62K | $15.62 | $40.84K | 2.3% | 111.35K | 108.74K |
| Total | +14.66K | -$40.84K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
69.10K shares
Shares
+69.10K
Strike price
15.92
Held after
69.10K
Exercisable
—
2/15/2024
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock69.10K shares | 2/15/2024 | A · Award | +69.10K | 15.92 | — | 69.10K |